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Inﬂammationisrecognizedasanimportantfactorinthepathophysiologyofhypertension,withtherenin-angiotensin-aldosterone
system (RAAS) playing a key role in the disease. Initially described because of its contribution to extracellular ﬂuid and electrolyte
homeostasis, the RAAS has been implicated in endothelial dysfunction, vascular remodeling, oxidative stress, proinﬂammatory
cytokine production, and adhesion molecule synthesis by the vascular wall. Both angiotensin II and aldosterone are involved in
these systemic eﬀects, activating innate and adaptive immune responses. This paper highlights some aspects connecting RAAS to
thehypertensivephenotype,basedonexperimentalandclinicalstudies,withemphasisonnewﬁndingsregardingthecontribution
of an increasingly studied population of T lymphocytes: the T-regulatory lymphocytes. These cells can suppress inﬂammation and
may exert beneﬁcial vascular eﬀects in animal models of hypertension.
1.Introduction
The major impact of hypertension on the population is well
recognized by health care providers and to some degree by
thegeneralpublic.DatafromtheInternationalHypertension
Society estimate that hypertension is associated with approx-
imately half of deaths caused by cardiovascular disease,
representing around eight million deaths per year around
the world [1]. Notwithstanding the importance on health
systems, the determinants of hypertension remain obscure
in the majority of patients seen on routine clinical practice,
whoaccordinglyarediagnosedashavingessentialorprimary
hypertension. This term was coined almost one century
ago, at a time when cell and molecular biology were just
beginning to appear as disciplines. Indeed, among the ﬁrst
reports of essential hypertension there is the paper by L.
M. Brown, who wrote in 1929: “I am presenting this type
of hypertension as a deﬁnite clinical entity, separate from
the high tension associated with diseases of the heart, kidney
and hyperthyroidism”[ 2]. One decade later, other authors
suggested that research on arterial hypertension would soon
lead to the replacement of the rather unspeciﬁc essential
hypertension by a number of hypertensive syndromes with
deﬁned and distinct pathophysiologic pathways [3].
More than sixty years have passed since these seminal
studies, and still most patients are diagnosed as having
essential hypertension. Nevertheless, we know much more
about the mechanisms involved in the genesis and progres-
sion of the disease. The role of mediators of the renin-
angiotensin-aldosterone system (RAAS), the contribution
of genetic polymorphisms, endothelial dysfunction, and
oxidative stress, among others, are features that evolve
in parallel and interact with each other, resulting in the
hypertensive phenotype.
In this paper we will focus on phenomena concerning
two vital systems which are deep-rooted in evolution and
are present in every vertebrate: the immune response and
RAAS. Both oﬀer the ability to cope with challenges imposed
by the environment, whether the exposure to an antigen (as
in inﬂammation), or a shift in water and sodium balance2 International Journal of Hypertension
(as is the case of RAAS), allowing the organism to keep
volume homeostasis despite wide variations in water and
sodium intake. We will also comment on oxidative stress,
one of the main mechanisms by which RAAS exerts its
proinﬂammatory actions in the vessel wall or the kidney.
Finally, we will deal with a special group of immune cells,
the regulatory T lymphocytes. This lymphocyte population
acts by suppressing inﬂammation and has been the object
of exciting recent studies about the interplay between blood
pressure, immune response, and RAAS.
2.The Renin-Angiotensin-Aldosterone
System and Inﬂammation
By far the best known properties of the RAAS have been,
since the ﬁrst description of renin in 1898 [4], linked to its
hemodynamic and pressor eﬀects. Accordingly, ﬁfty years
ago many aspects were known about the actions of RAAS
on kidney sodium and water reabsorption, as well as the
vasoconstrictor eﬀects of angiotensin (Ang) II. The ﬁrst
reports associating inﬂammation and high blood pressure
appeared at this time [5]. Nevertheless, studies establishing
the connection between the RAAS and the immunologic
response would be published only in the following decades.
In one of the ﬁrst works of immune involvement in
hypertension, Rodriguez-Iturbe et al. demonstrated that
chronic Ang II infusion caused renal inﬁltration of T
lymphocytes in rats. This eﬀect was blunted by the treatment
with the immunosuppressor mycophenolate mofetil, whose
actions were independent of arterial pressure [6]. Further
studieshaveshownthatbothAngIIandaldosterone,inasso-
ciation with inﬂammatory mediators such as interferon-γ
(IFN-γ) and tumour necrosis factor α (TNF-α), are able
to stimulate growth and proliferation of vascular smooth
muscle cells (VSMCs), leading to vascular hypertrophy
characteristic of hypertension [7].
In another set of studies linking RAAS and inﬂamma-
tion, the contribution of macrophages in Ang II-induced
vascular lesions was evaluated in animals with impairment
of innate immunity, the osteopetrotic (Op) mice [8]. These
animals display macrophage deﬁciency due to a mutation
of macrophage colony-stimulating factor (mCSF)g e n e .O p
mice did not develop hypertension, endothelial dysfunction,
and vascular remodelling when subjected to chronic Ang II
infusion, when compared to control. The role of monocytes
in Ang II-induced vascular eﬀects was further demonstrated
by Wenzel et al. [9]. In transgenic mice (LysMiDTR)s u b j e c t e d
to conditional depletion of myelomonocytic cells, there
was a reduction in Ang II-induced hypertension, vascular
dysfunction, and oxidative stress. Reconstitution of depleted
mice with the adoptive transfer of monocytes, but not
neutrophils, reestablished the aforementioned features.
The association of adaptive immunity in Ang II-induced
hypertension was also studied by Shao et al., who showed
that Ang II infusion in rats triggered lymphocyte recruit-
ment to the kidney [10]. This eﬀect was prevented by
the angiotensin type I receptor blocker olmesartan, but
not by the vasodilator hydralazine. The importance of T
lymphocytes in the genesis of vascular lesions induced by
Ang II was shown in mice by Guzik et al. [11]. Using animals
lackingTandBlymphocytes(rag-1−/−),theauthorsdemon-
strated that hypertension, endothelial dysfunction, vascular
remodelling, and superoxide production induced by Ang II
were reduced in rag-1−/− miceandrestoredbyT-lymphocyte
adoptive transfer, but not when B lymphocytes were used.
In addition, the same paper showed that treatment with
e t a n e r c e p t ,aT N F - α inhibitor, prevented Ang II-induced
hypertension and superoxide generation.
Ang II can modulate adaptive immunity, acting directly
on lymphocytes. Both T and B lymphocytes express
angiotensin type 1a receptors (AT1aR) in mice, and in vitro,
Ang II stimulates the proliferation of splenic lymphocytes
[12]. These ﬁndings, added to evidences that Ang II and
its precursors, angiotensinogen and Ang I, are capable
of inducing human T lymphocyte and Natural Killer cell
(NK) proliferation [13], have suggested the presence of
an intracellular RAAS. In addition, human T lymphocytes
express renin and its receptors, angiotensinogen, angiotensin
I-converting enzyme (ACE), and angiotensin II receptors
typeIandII.Inasimilarway,mouseTlymphocytesexpressa
local RAAS, regulating lymphocyte activation, tissue homing
markers, and the production of TNF-α [14].
A new mechanism linking inﬂammation and high blood
pressure mediated by Ang II was proposed by Marvar et al.
Using mice subjected to a lesion in the anteroventral region
of the third cerebral ventricle and infused with Ang II for 2
weeks, these authors observed a blunting of Ang II pressor
eﬀects, vascular oxidative stress, circulating T-lymphocyte
activation, and their vascular inﬁltration [15]. In a subset
of experiments in the same study, hydralazine blunted Ang
II-induced hypertension, and this was associated with a
reduction in lymphocyte activation. However, there was
no evidence of a direct hydralazine action on the capacity
of lymphocytes to display antigen-speciﬁc activation. The
authors suggested that Ang II eﬀects on the central nervous
system caused an elevation of blood pressure that could in
turn activate T lymphocytes and vascular inﬂammation.
Within the RAAS, aldosterone is the mediator stimulated
by Ang II and contributes to the sequence of events
leading to hypertension. There is abundant evidence linking
aldosterone to target organ lesions, in association with
oxidativestressandinﬂammation.Inexperimentalmodelsof
hypertension, treatment with the mineralocorticoid receptor
(MR) blocker spironolactone was able to reduce cerebral and
renal vascular lesions, cardiac hypertrophy, inﬂammation,
and extracellular matrix synthesis [16]. Rocha et al. have
shown that aldosterone infusion for 4 weeks, associated
with an increase in sodium intake, produced extended
arterial inﬂammatory lesions, with myocardial perivascular
macrophage deposition [17]. The selective MR blocker
eplerenone reduced this inﬂammatory response. The bene-
ﬁcial eﬀects of this drug were also veriﬁed in the peripheral
vasculature, with reduction of inﬂammatory cell inﬁltration,
ﬁbrosis, and aortic hypertrophy in hypertensive rats [18].
An interesting interplay between Ang II and aldosterone was
described by Virdis et al. In rats chronically infused with
Ang II, spironolactone treatment blunted Ang II-inducedInternational Journal of Hypertension 3
endothelial dysfunction, resistance artery remodeling, and
aortic redox state [19]. These ﬁndings underscore that
vasculardamagecausedbyAngIIismediated,atleastinpart,
via stimulation by aldosterone of the MR receptor.
Both human and experimental model researches have
shown that aldosterone can act directly on vessel wall com-
ponents and inﬂammatory cells. Human VSMCs exposed to
aldosterone present an increase in type I and III collagen,
interleukin-(IL-)16,andcytotoxicT-lymphocyte-associated
protein 4 expression, molecules associated with ﬁbrosis,
inﬂammation, and vascular calciﬁcation [20]. Macrophages
possess MR and its expression increases in response to
INF-γ,secretedbyTlymphocytes[21].Inaddition,Leibovitz
et al. demonstrated that in Op mice, chronic aldosterone
infusion does not induce endothelial dysfunction and vascu-
lar cell adhesion molecule (VCAM-1) expression, providing
additional evidence for the role of inﬂammatory cells and
speciﬁcally macrophages in aldosterone-induced vascular
damage [22].
3. Inﬂammation and OxidativeStress
Studies on immunity and hypertension show a close rela-
tionshipbetweeninﬂammatorycellinﬁltrationandoxidative
stress in cardiovascular tissues. Indeed, one of the main
mechanisms by which RAAS causes vascular pathology
in hypertension involves reactive oxygen species (ROS)
production. Superoxide (
￿O2
−), hydroxyl radical (OH−)
and hydrogen peroxide (H2O2), and lipid peroxidation
unstable products belong to this group of chemically reactive
compounds [23]. Free radicals are able to interact with
virtually all biologic molecules, including lipids, proteins,
nucleic acids, carbohydrates, and nitric oxide (NO). They
are involved in cell growth and proliferation as well as
extracellular matrix expansion. The consequences of ROS
production on the cardiovascular system are cell injury and
endothelial dysfunction, since free radicals inactivate NO,
transforming it into peroxynitrite, which leads to impaired
vasodilation [24].
Studies performed in the last decade have helped elu-
cidate mechanisms whereby the RAAS causes ROS eleva-
tion. Both Ang II and aldosterone induce the expression
of reduced nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, the main enzyme responsible for the pro-
duction of superoxide in vascular tissue [26]. Free radicals,
in turn, act as activators of inﬂammation. Oxidative stress
triggers an inﬂammatory process by stimulating vascular
permeability, increasing the secretion of mediators such
as prostaglandins and vascular endothelial growth factor
(VEGF) [27]. The next steps, represented by adhesion and
diapedesisofinﬂammatorycellsintothevasculature,arealso
governedbyROSproduction.AngIIincreasestheexpression
of cell adhesion molecules VCAM-1, intercellular cell adhe-
sion molecule 1 (ICAM-1), and E-selectin through signaling
pathways involving ROS production. This phenomenon is
ampliﬁed by vessel wall invasion by inﬂammatory cells,
which are rich in NADPH oxidase and enhance local
oxidative stress [28]. At the end of the process, tissue repair
mechanisms are also aﬀected by oxidative stress. Both Ang
II and aldosterone stimulate hyperplasia, hypertrophy, and
apoptosis, as well as vascular ﬁbrosis [29]. The resulting
cell proliferation and matrix deposition, mainly collagen
and ﬁbronectin, produce vascular remodelling and increased
vascular stiﬀness. Taking into account the aforementioned
features leading to target organ lesion, therapeutic inter-
ventions aiming to modulate vascular redox state, as well
as immunological activation, could reduce hypertension
morbidity.
4. T-Regulatory Lymphocyte and Hypertension
A speciﬁc subset of T lymphocytes has recently become the
focus of studies on inﬂammation-linked vascular lesions. T-
regulatory lymphocytes (Treg) can suppress inﬂammatory
a c t i o n so fo t h e rl y m p h o c y t e s ,a sw e l la sm a c r o p h a g e s ,
dendritic cells and neutrophils [30]. Initially evaluated in
the context of autoimmune diseases, graft rejection, and
malignancies, Treg properties are increasingly recognized in
cardiovascular disease.
T h eﬁ r s tr e p o r t so fap o p u l a t i o no fC D 4 + T cells able
to suppress immunological reactions were published more
than 20 years ago. One of the seminal studies used a
model of lymphocyte infusion in rats, which could reduce
host rejection to cardiac transplantation [31]. Shortly after,
the characterization of a subset of CD4+CD25+ Tc e l l s
able to suppress innate and adaptive immune responses
was accomplished. An important advance in the knowledge
of these cells was the description of patients bearing the
IPEX syndrome (immune dysregulation, polyendocrinopa-
thy, enteropathy, X-linked), a fatal disease characterized by
the development of autoimmune disorders in the ﬁrst years
of life due to a mutation in the transcription factor forkhead
box protein 3 (Foxp3) [32]. Other studies conﬁrmed Foxp3
as the transcription factor necessary for the maturation of
CD4+ T lymphocytes into Treg. A reduction in Treg is
associated with the development of autoimmune diseases in
both humans and experimental animals [33].
There are several mechanisms that have been proposed
through which Tregs suppress proinﬂammatory actions of
other T-lymphocyte subtypes. The Treg surface marker
CD25 is a receptor of IL-2, a cytokine produced by T-eﬀector
cells and ampliﬁer of the inﬂammatory response, promoting
Th1-associated gene expression in immature thymocytes
[34]. Following CD25 binding, IL-2 is internalized and
degraded, hence reducing its bioavailability [35]. Treg can
also secrete inhibitory cytokines IL-35 and IL-10 [36], which
produce cell cycle arrest, leading to an interruption of
inﬂammatory cell clonal expansion. Alternative mechanisms
for Treg eﬀects include lysis of target cells through the secre-
tion of granzyme B and the expression of galectin-1 [37],
causing a blockade in the production of proinﬂammatory
cytokines by other T lymphocytes and their apoptosis.
Recently, we performed studies looking at the interaction
betweeninﬂammatorycellsinaRAASactivationexperimen-
tal model using Treg adoptive transfer. In mice receiving
chronic Ang II infusion, Treg intravenous administration4 International Journal of Hypertension
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Figure 1: T-regulatory lymphocyte (Treg) adoptive transfer pre-
ventedangiotensinII(AngII)-inducedhypertension.Systolicblood
pressure (SBP) was evaluated by telemetry in mice chronically
infused with Ang II and pretreated with PBS or Treg. Mean daily
SBP data are presented. Data are expressed as means ± SEM. †P <
0,05 e ††P < 0,001 versus PBS + Ang II with n = 24 data points per
day for each 3 to 4 mice. Adapted from [25].
prevented high blood pressure, vascular oxidative stress
and macrophage, and T-cell inﬁltration in aorta, when
compared to untreated hypertensive animals [25]. The blood
pressure result can be seen in Figure 1. Similar ﬁndings
were observed when Tregs were administered to aldosterone-
infused animals, although in this case the eﬀect on blood
pressure was negligible [38]. These results show that the
RAAS proinﬂammatory actions on both innate and adaptive
immune responses run in concert with oxidative proﬁle and
pressor eﬀects, and all have the capacity to be modulated by
interventions that target the immune system.
5. Conclusion
Multiple research lines associate cardiovascular disease,
including hypertension, to a low-level chronic inﬂammatory
state. Current evidence in favour to this at least with
respect to high blood pressure is predominantly based on
experimental models of hypertension, although increases in
C - r e a c t i v ep r o t e i n( am a r k e ro fs y s t e m i ci n ﬂ a m m a t i o n )i n
human subjects have been correlated with both incident
hypertension and the level of blood pressure elevation,
independent of other cardiovascular risk factors [39, 40].
Theexpectationexpressedbyhypertensionresearchersin
the beginning of the last century that essential hypertension
would be replaced by other terms with precise pathophys-
iological characteristics has not been fulﬁlled yet. Indeed,
the multifactorial nature of hypertensive mechanisms makes
it diﬃcult to identify a predominant mediator in most
cases. However, the vast number of studies that followed
the ﬁrst descriptions of essential hypertension has allowed
an understanding of the contribution of new mechanisms.
The eﬀects of Ang II and aldosterone are mediated, at least
in part, by the production of ROS by macrophages. Cellular
and molecular immunological phenomena causing vascular
damage in hypertension represent a new frontier in research
that could result in an improvement of our therapeutic
armamentarium for cardiovascular disease.
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